Better Health. Better Life.

M Pharmaceutical Inc. announces the appointment of Dr. Martin Mintchev as President & Chief Executive Officer

VANCOUVER (April 15, 2015) - M Pharmaceutical Inc., (the "Company") (CSE:MQ) announces that medical technology pioneer Dr. Martin Mintchev has accepted the position of President & Chief Executive Officer.

Dr. Mintchev is the primary developer of the innovative medical technologies held by M Pharmaceutical. The company is focused on two groups of medical devices developed to enhance the quality of life of people living with diabetes and/or obesity, including the eMosquito currently held by M Pharmaceutical and the pseudobezoar technologies acquired through the purchase of RX Global Capital Inc.

A veteran academic in the field, Dr. Mintchev will continue his role as a Professor in the Schulich School of Engineering at the University of Calgary, but will be able to devote the leadership required in order to move forward the development of the Company's medical devices.

“This company represents an opportunity to apply the expertise I have gained over decades in order to deliver realistic solutions that reduce invasiveness and enhance effectiveness for millions of people who require more options when facing obesity and diabetes,” said Dr. Mintchev, a native of  Bulgaria who holds the designations of PhD and PEng.

The Board of Directors of M Pharmaceutical, Inc. wishes to thank David Lane for his work and service to the company as its former president and director.

The Company also announces that it will effect a 10 to one consolidation of its issued and outstanding shares, effective April 16, 2015. No fractional shares will be issued, and fractions will be rounded to the nearest whole number. The consolidation will result in the Company holding a capital structure more in line with its peers in the field.

About M Pharmaceutical Inc.

M Pharmaceutical, Inc is focused on addressing the chronic disease epidemic by providing medical technologies that improve the health and quality of life for people affected by diabetes and obesity. The Company has the rights to a biomedical device for the self-monitoring of blood glucose, primarily by diabetics. This device, called the eMosquito, is based on a novel in-plane actuator designed to provide minimally-invasive skin penetration to be used by persons with diabetes.  The objective of the eMosquito is to obtain whole blood samples by penetrating the skin to shallower depths and in less sensitive areas of the body.  Persons with diabetes have traditionally used the "finger prick" method to monitor/test their blood glucose levels.  The blood sample was obtained by pricking the finger tip, a highly sensitive area of the body.  The eMosquito is envisioned to be worn like a patch with small needles designed to puncture the skin just deep enough to draw blood without affecting the nerve endings and causing little or no pain.  The commercial development of the eMosquito will require the successful coordination and execution of a wide variety of technology disciplines.

For more information contact:

Investor Relations
Phone: 604.428.0511  


This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the acquisition of RX Global, and the commercialization of the rights to the eMosquito and the temporary pseudobezoars.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on and such factors as the Company failing to acquire RX Global and the failure to complete the commercialization of the eMosquito and the temporary pseudobezoars.

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.